{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:29:40Z","timestamp":1774373380264,"version":"3.50.1"},"reference-count":56,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/CTM-BIO\/4388\/2014"],"award-info":[{"award-number":["PTDC\/CTM-BIO\/4388\/2014"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BPD\/73322\/2010"],"award-info":[{"award-number":["SFRH\/BPD\/73322\/2010"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BPD\/96176\/2013"],"award-info":[{"award-number":["SFRH\/BPD\/96176\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["IF\/00735\/2014"],"award-info":[{"award-number":["IF\/00735\/2014"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["IF\/00376\/2014"],"award-info":[{"award-number":["IF\/00376\/2014"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nanomaterials"],"abstract":"<jats:p>Rheumatoid arthritis (RA) is an autoimmune disease that affects the synovial cavity of joints, and its pathogenesis is associated with an increased expression of pro-inflammatory cytokines, namely tumour necrosis factor-alpha (TNF-\u03b1). It has been clinically shown to have an adequate response to systemic administration of TNF-\u03b1 inhibitors, although with many shortcomings. To overcome such limitations, the immobilization of a TNF-\u03b1 antibody on a nanofibrous substrate to promote a localized action is herein proposed. By using this approach, the antibody has its maximum therapeutic efficacy and a prolonged therapeutic benefit, avoiding the systemic side-effects associated with conventional biological agents\u2019 therapies. To technically achieve such a purpose, the surface of electrospun nanofibers is initially activated and functionalized, allowing TNF-\u03b1 antibody immobilization at a maximum concentration of 6 \u00b5g\/mL. Experimental results evidence that the biofunctionalized nanofibrous substrate is effective in achieving a sustained capture of soluble TNF-\u03b1 over time. Moreover, cell biology assays demonstrate that this system has no deleterious effect over human articular chondrocytes metabolism and activity. Therefore, the developed TNF-capturing system may represent a potential therapeutic approach for the local management of severely affected joints.<\/jats:p>","DOI":"10.3390\/nano9040567","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T11:54:52Z","timestamp":1554724492000},"page":"567","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Biofunctional Nanofibrous Substrate for Local TNF-Capturing as a Strategy to Control Inflammation in Arthritic Joints"],"prefix":"10.3390","volume":"9","author":[{"given":"Elisa","family":"Bacelo","sequence":"first","affiliation":[{"name":"3B\u2019s Research Group, I3Bs\u2014Research Institute of Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark\u2014Parque de Ci\u00eancia e Tecnologia, Zona Industrial da Gandra, University of Minho, Barco, 4805-017 Guimar\u00e3es, Portugal"},{"name":"ICVS\/3B\u2019s\u2014PT Government Associate Laboratory, Barco, 4805-017 Guimar\u00e3es, Portugal"}]},{"given":"Marta","family":"Alves da Silva","sequence":"additional","affiliation":[{"name":"3B\u2019s Research Group, I3Bs\u2014Research Institute of Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark\u2014Parque de Ci\u00eancia e Tecnologia, Zona Industrial da Gandra, University of Minho, Barco, 4805-017 Guimar\u00e3es, Portugal"},{"name":"ICVS\/3B\u2019s\u2014PT Government Associate Laboratory, Barco, 4805-017 Guimar\u00e3es, Portugal"}]},{"given":"Cristina","family":"Cunha","sequence":"additional","affiliation":[{"name":"ICVS\/3B\u2019s\u2014PT Government Associate Laboratory, Barco, 4805-017 Guimar\u00e3es, Portugal"},{"name":"Life and Health Sciences Research Institute, Scholl of Medicine, Campus of Gualtar, University of Minho, 4710-057 Braga, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8014-9902","authenticated-orcid":false,"given":"Susana","family":"Faria","sequence":"additional","affiliation":[{"name":"Department of Mathematics for Science and Technology Research CMAT, Campus of Azur\u00e9m, University of Minho, 4800-058 Guimar\u00e3es, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-8030","authenticated-orcid":false,"given":"Agostinho","family":"Carvalho","sequence":"additional","affiliation":[{"name":"ICVS\/3B\u2019s\u2014PT Government Associate Laboratory, Barco, 4805-017 Guimar\u00e3es, Portugal"},{"name":"Life and Health Sciences Research Institute, Scholl of Medicine, Campus of Gualtar, University of Minho, 4710-057 Braga, Portugal"}]},{"given":"Rui L.","family":"Reis","sequence":"additional","affiliation":[{"name":"3B\u2019s Research Group, I3Bs\u2014Research Institute of Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark\u2014Parque de Ci\u00eancia e Tecnologia, Zona Industrial da Gandra, University of Minho, Barco, 4805-017 Guimar\u00e3es, Portugal"},{"name":"ICVS\/3B\u2019s\u2014PT Government Associate Laboratory, Barco, 4805-017 Guimar\u00e3es, Portugal"},{"name":"The Discoveries Centre for Regenerative and Precision Medicine, Headquarters at University of Minho, Avepark, Barco, 4805-017 Guimar\u00e3es, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3868-0251","authenticated-orcid":false,"given":"Albino","family":"Martins","sequence":"additional","affiliation":[{"name":"3B\u2019s Research Group, I3Bs\u2014Research Institute of Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark\u2014Parque de Ci\u00eancia e Tecnologia, Zona Industrial da Gandra, University of Minho, Barco, 4805-017 Guimar\u00e3es, Portugal"},{"name":"ICVS\/3B\u2019s\u2014PT Government Associate Laboratory, Barco, 4805-017 Guimar\u00e3es, Portugal"}]},{"given":"Nuno M.","family":"Neves","sequence":"additional","affiliation":[{"name":"3B\u2019s Research Group, I3Bs\u2014Research Institute of Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark\u2014Parque de Ci\u00eancia e Tecnologia, Zona Industrial da Gandra, University of Minho, Barco, 4805-017 Guimar\u00e3es, Portugal"},{"name":"ICVS\/3B\u2019s\u2014PT Government Associate Laboratory, Barco, 4805-017 Guimar\u00e3es, Portugal"},{"name":"The Discoveries Centre for Regenerative and Precision Medicine, Headquarters at University of Minho, Avepark, Barco, 4805-017 Guimar\u00e3es, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000289195","article-title":"Cellular mechanisms of TNF function in models of inflammation and autoimmunity","volume":"11","author":"Apostolaki","year":"2010","journal-title":"Curr. Dir. Autoimmun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5312\/wjo.v5.i4.544","article-title":"Rheumatoid arthritis susceptibility genes: An overview","volume":"5","author":"Korczowska","year":"2014","journal-title":"World J. Orthop."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","article-title":"Rheumatoid arthritis","volume":"373","author":"Klareskog","year":"2009","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"J109","DOI":"10.1016\/j.jaut.2011.10.003","article-title":"Autoimmune disease and gender: Plausible mechanisms for the female predominance of autoimmunity","volume":"38","author":"Quintero","year":"2012","journal-title":"J. Autoimmun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease","volume":"35","author":"Ngo","year":"2014","journal-title":"Front. Neuroendocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"A386","DOI":"10.1016\/j.autrev.2011.11.012","article-title":"Geoepidemiology, gender and autoimmune disease","volume":"11","author":"Moroni","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"J254","DOI":"10.1016\/j.jaut.2011.12.001","article-title":"Sex differences and genomics in autoimmune diseases","volume":"38","author":"Amur","year":"2012","journal-title":"J. Autoimmun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"A377","DOI":"10.1016\/j.autrev.2011.11.001","article-title":"The role of gender and organ specific autoimmunity","volume":"11","author":"Nussinovitch","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"J282","DOI":"10.1016\/j.jaut.2011.11.013","article-title":"Sex affects immunity","volume":"38","author":"Pennell","year":"2012","journal-title":"J. Autoimmun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.autrev.2011.04.021","article-title":"An overview on the genetic of rheumatoid arthritis: A never-ending story","volume":"10","author":"Perricone","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-013-0063-0","article-title":"Tumour necrosis factor \u03b1 antagonists in the treatment of rheumatoid arthritis: An immunological perspective","volume":"28","author":"Meroni","year":"2014","journal-title":"BioDrugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Mcinnes, I.B., and Schett, G. (2012). The Pathogenesis of Rheumatoid Arthritis. N. Engl. J. Med., 2205\u20132219.","DOI":"10.1056\/NEJMra1004965"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1186\/ar556","article-title":"Cytokine regulation in RA synovial tissue: Role of T cell\/macrophage contact-dependent interactions","volume":"4","author":"Brennan","year":"2002","journal-title":"Arthritis Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1542\/neo.2-5-e103","article-title":"The pathophysiology of necrotizing enterocolitis","volume":"2","author":"Caplan","year":"2001","journal-title":"NeoReviews"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1385\/MB:19:2:153","article-title":"Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases","volume":"19","author":"Taylor","year":"2001","journal-title":"Mol. Biotechnol."},{"key":"ref_19","first-page":"469","article-title":"Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: Correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions","volume":"23","author":"Edrees","year":"2005","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/rheumatology\/kes114","article-title":"Assessing the safety of biologic agents in patients with rheumatoid arthritis","volume":"51","year":"2012","journal-title":"Rheumatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis","volume":"334","author":"Brennan","year":"1989","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-\u03b1: Structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrd3030","article-title":"TNF receptor 2 pathway: Drug target for autoimmune diseases","volume":"9","author":"Faustman","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/338225a0","article-title":"Structure of tumour necrosis factor","volume":"338","author":"Jones","year":"1989","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","article-title":"The Tumor Necrosis Factor Ligand and receptor families","volume":"334","author":"Bazzoni","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0962-8924(00)89088-1","article-title":"Two tumour necrosis factor receptors: Structure and function","volume":"5","author":"Vandenabeele","year":"1995","journal-title":"Trends Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.trsl.2014.09.006","article-title":"Tumor necrosis factor inhibitors: Clinical utility in autoimmune diseases","volume":"165","author":"Willrich","year":"2015","journal-title":"Transl. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.it.2011.10.004","article-title":"TNF superfamily in inflammatory disease: Translating basic insights","volume":"33","author":"Croft","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrrheum.2010.179","article-title":"Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis","volume":"6","author":"Hoes","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrrheum.2014.64","article-title":"Mechanisms, impact and management of pain in rheumatoid arthritis","volume":"10","author":"Walsh","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.intimp.2015.03.019","article-title":"Rheumatoid arthritis: Biological therapy other than anti-TNF","volume":"27","author":"Rossi","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/ten.teb.2009.0536","article-title":"Impact of biological agents and tissue engineering approaches on the treatment of rheumatic diseases","volume":"16","author":"Martins","year":"2010","journal-title":"Tissue Eng. Part B Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum."},{"key":"ref_34","first-page":"449","article-title":"Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: Prolonged production of IL-1 alpha","volume":"73","author":"Buchan","year":"1988","journal-title":"Clin. Exp. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/eji.1830211039","article-title":"Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-alpha","volume":"21","author":"Haworth","year":"1991","journal-title":"Eur. J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","article-title":"Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis","volume":"89","author":"Williams","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.autrev.2013.03.015","article-title":"Biologic therapies and systemic bone loss in rheumatoid arthritis","volume":"12","author":"Dimitroulas","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_39","first-page":"1308","article-title":"Modern anti-cytokine therapy of autoimmune diseases","volume":"79","author":"Astrakhantseva","year":"2014","journal-title":"Biochemistry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/13543776.18.7.723","article-title":"The development of novel therapies for rheumatoid arthritis","volume":"18","author":"Quan","year":"2008","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1517\/17425247.5.9.1027","article-title":"Drug delivery systems for the treatment of rheumatoid arthritis","volume":"5","author":"Tarner","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5731\/pdajpst.2013.00919","article-title":"Preparation and evaluation of sustained release infliximab microspheres","volume":"67","author":"Gokhale","year":"2013","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1039\/C5TB00397K","article-title":"Surface engineering of porous silicon to optimise therapeutic antibody loading and release","volume":"3","author":"McInnes","year":"2015","journal-title":"J. Mater. Chem. B"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jconrel.2013.07.012","article-title":"Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis","volume":"171","author":"Jung","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1021\/bm100476r","article-title":"Cartilage Tissue Engineering Using Electrospun PCL Nanofiber Meshes and MSCs","volume":"11","author":"Martins","year":"2010","journal-title":"Biomacromolecules"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/term.1812","article-title":"Conditioned medium as a strategy for human stem cells chondrogenic differentiation","volume":"9","author":"Martins","year":"2015","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.apsusc.2016.12.135","article-title":"Chondroitin sulfate immobilization at the surface of electrospun nanofiber meshes for cartilage tissue regeneration approaches","volume":"403","author":"Piai","year":"2017","journal-title":"Appl. Surf. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1021\/bm500346s","article-title":"Biofunctional nanofibrous substrate comprising immobilized antibodies and selective binding of autologous growth factors","volume":"15","author":"Oliveira","year":"2014","journal-title":"Biomacromolecules"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1039\/C4BM00069B","article-title":"Immobilization of bioactive factor-loaded liposomes on the surface of electrospun nanofibers targeting tissue engineering","volume":"2","author":"Monteiro","year":"2014","journal-title":"Biomater. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0142-9612(94)90054-X","article-title":"Colorimetric determination of reactive solid-supported primary and secondary amino groups","volume":"15","author":"Kakabakos","year":"1994","journal-title":"Biomaterials"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0003-2697(79)90792-9","article-title":"Ellman\u2019s reagent: 5,5\u2032-dithiobis(2-nitrobenzoic acid)\u2014A reexamination","volume":"94","author":"Riddles","year":"1979","journal-title":"Anal. Biochem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.autrev.2008.11.003","article-title":"Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal","volume":"8","author":"Caporali","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0378-4347(98)00434-4","article-title":"Oriented immobilization of biologically active proteins as a tool for revealing protein interactions and function","volume":"722","year":"1999","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"R119","DOI":"10.1186\/ar4299","article-title":"Interleukin-1 beta and tumor necrosis factor alpha inhibit migration activity of chondrogenic progenitor cells from non-fibrillated osteoarthritic cartilage","volume":"15","author":"Joos","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s13075-014-0441-0","article-title":"Cytokine profiles in the joint depend on pathology, but are different between synovial fluid, cartilage tissue and cultured chondrocytes","volume":"16","author":"Tsuchida","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Timmen, M., Hidding, H., Wiesk\u00f6tter, B., Baum, W., Pap, T., Raschke, M.J., Schett, G., Zwerina, J., and Stange, R. (2014). Influence of antiTNF-alpha antibody treatment on fracture healing under chronic inflammation. BMC Musculoskelet. Disord., 15.","DOI":"10.1186\/1471-2474-15-184"}],"container-title":["Nanomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-4991\/9\/4\/567\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:43:38Z","timestamp":1760186618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-4991\/9\/4\/567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["nano9040567"],"URL":"https:\/\/doi.org\/10.3390\/nano9040567","relation":{},"ISSN":["2079-4991"],"issn-type":[{"value":"2079-4991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]}}}